— Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter 2019 adjusted earnings of $8.34 per share versus $8.02 per share expected.
— Total revenues increased by 4% to $3.67 billion versus $3.54 billion expected.
— Total product revenues rose by 4% driven by growth in multiple sclerosis drugs, spinal muscular atrophy drug Spinraza, biosimilars Benepali, Imraldi, and Flixabi.
— Research and development expense rose by 13% due to the inclusion of charges related to Samsung Bioepis transaction, related to the option exercise with Ionis Pharmaceuticals, and related to collaboration agreements with CAMP24 Therapeutics and Catalyst Biosciences.
— Looking ahead into the full year 2020, the company expects revenue in the range of $14-14.3 billion and adjusted earnings in the range of $31.50-33.50 per share. Analysts expect EPS of $33.03 on revenue of $14.06 billion.
— The earnings are anticipated to be in the range of $29.50-31.50 per share for the full year.
Most Popular
Earnings Preview: Target (TGT) expected to report lower Q3 2025 sales and profit
Target Corporation (NYSE: TGT) is navigating a challenging retail landscape ahead of next week's earnings, as sales and margins face pressure from economic uncertainty and restrained consumer demand. With a
Home Depot (HD) expected to report higher revenue and earnings in Q3 2025
Shares of The Home Depot (NYSE: HD) dipped over 1% on Monday. The stock has dropped 5% in the past three months. The home improvement retailer is scheduled to report
Tyson Foods (TSN) Q4 2025 adj. earnings beat unexpectedly; sales up 2%
Tyson Foods, Inc. (NYSE: TSN), a leading processor and marketer of chicken, beef, and pork, reported stronger-than-expected earnings for the fourth quarter of fiscal 2025 when the company's sales rose
